TNF and myeloid sarcoma: TNF-α, a major mediator of inflammation in MS (33), was significantly increased in both CD19+ B-cells and CD8+-T cells after exposure to pHERV-Wenv 486–504, especially in RR-SMS and PP-MS patients and was higher compared to HCs.